

MarÃ-a Reig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5129924/publications.pdf>

Version: 2024-02-01

124
papers

15,961
citations

61945

43
h-index

17580

121
g-index

139
all docs

139
docs citations

139
times ranked

14524
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	6.1	62
2	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 283-292.e10.	2.4	94
3	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84.	4.2	29
4	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2022, 76, 874-882.	1.8	17
5	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
6	Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study. <i>Lancet Oncology</i> , The, 2022, 23, 4-6.	5.1	3
7	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. <i>Hepatology</i> , 2022, 76, 139-154.	3.6	42
8	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. <i>Gastroenterology</i> Y <i>Hepatology</i> , 2022, , .	0.2	1
9	Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. <i>Journal of Clinical Oncology</i> , 2022, 40, 428-428.	0.8	6
10	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	1.8	139
11	Reply to: "Correspondence on the BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update"; <i>Journal of Hepatology</i> , 2022, 76, 1240-1241.	1.8	2
12	POLYETHYLENE-GLYCOL DRUG-ELUTING EMBOLIC MICROSPHERES LOADED WITH DOXORUBICIN FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY, SAFETY AND PHARMACOKINETIC STUDY. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.2	2
13	Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. <i>Hepatology</i> , 2022, 76, 1318-1328.	3.6	10
14	DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis. <i>Cancers</i> , 2022, 14, 2048.	1.7	5
15	THE COMPLEX MANAGEMENT OF HEPATOCELLULAR CARCINOMA: A MAJOR NEED OF EXPERTISE. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	0
16	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	1.9	11
17	Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR. <i>Radiology and Oncology</i> , 2022, 56, 292-302.	0.6	0
18	Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. <i>Gastrointestinal Disorders</i> , 2022, 4, 141-152.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	1.9	13
20	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 426.	1.7	4
21	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. <i>European Radiology</i> , 2021, 31, 4794-4803.	2.3	8
22	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021, 135, 109484.	1.2	20
23	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021, 12, 440-449.	0.8	1
24	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021, 12, 555.	2.7	10
25	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). <i>Journal of Hepatology</i> , 2021, 74, 1225-1233.	1.8	42
26	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.1	16
27	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	2.6	36
28	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021, 75, 1154-1163.	1.8	9
29	The TGF- β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. <i>Cancers</i> , 2021, 13, 3248.	1.7	37
30	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , 2021, 9, 655-661.	1.6	2
31	Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species. <i>Antioxidants</i> , 2021, 10, 1336.	2.2	11
32	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	1.3	19
33	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 600-609.	1.8	127
34	Current pharmacological treatment of hepatocellular carcinoma. <i>Current Opinion in Pharmacology</i> , 2021, 60, 141-148.	1.7	12
35	Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. <i>European Journal of Medical Genetics</i> , 2021, 64, 104313.	0.7	19
36	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 263-270.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 90.	1.7	21
38	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 186-194.	2.3	25
39	Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 710-719.	0.2	25
40	Reply to: "The reported "clear cut time association between interferon-free treatment and HCC" is anything but clear cut". <i>Journal of Hepatology</i> , 2020, 72, 1036-1037.	1.8	1
41	Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 192-192.	1.9	0
42	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 719-737.	1.0	29
43	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020, 40, 2476-2488.	1.9	6
44	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 3446.	1.7	19
45	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020, 52, 1041-1046.	0.4	13
46	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	1.9	15
47	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020, 30, 6694-6701.	2.3	8
48	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	1.8	165
49	Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. <i>Cancers</i> , 2020, 12, 332.	1.7	13
50	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 617-630.	8.2	132
51	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	2.6	60
52	Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals. <i>Gastroenterology & Hepatology (English Edition)</i> , 2019, 42, 502-511.	0.0	3
53	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 482-491.	1.9	40
54	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	1.8	67

#	ARTICLE	IF	CITATIONS
55	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" A response. Journal of Hepatology, 2019, 71, 447-448.	1.8	0
56	Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. Viruses, 2019, 11, 406.	1.5	11
57	SAT-482-Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease: Results from a prospective screening program. Journal of Hepatology, 2019, 70, e845.	1.8	2
58	Controversies in the management of hepatocellular carcinoma. JHEP Reports, 2019, 1, 17-29.	2.6	45
59	Should Patients With NAFLD/NASH Be Surveyed for HCC?. Transplantation, 2019, 103, 39-44.	0.5	52
60	New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transplantation, 2019, 25, 311-322.	1.3	21
61	Riesgo de recurrencia del carcinoma hepatocelular en pacientes tratados con antivirales libres de interferón. Gastroenterología Y Hepatología, 2019, 42, 502-511.	0.2	7
62	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. Journal of Clinical Oncology, 2019, 37, 327-327.	0.8	80
63	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncology, The, 2018, 19, 682-693.	5.1	285
64	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterología Y Hepatología, 2018, 41, 328-349.	0.2	71
65	New trials and results in systemic treatment of HCC. Journal of Hepatology, 2018, 69, 525-533.	1.8	49
66	Lenvatinib: can a non-inferiority trial change clinical practice?. Lancet, The, 2018, 391, 1123-1124.	6.3	12
67	Hepatocellular carcinoma. Lancet, The, 2018, 391, 1301-1314.	6.3	3,878
68	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology, 2018, 67, 612-622.	3.6	55
69	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget, 2018, 9, 16701-16717.	0.8	44
70	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterología Y Hepatología (English Edition), 2018, 41, 328-349.	0.0	7
71	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews, 2018, 68, 16-24.	3.4	124
72	Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success. Oncotarget, 2018, 9, 33741-33742.	0.8	1

#	ARTICLE	IF	CITATIONS
73	The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 136-139.	1.9	31
74	Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. <i>Journal of Hepatology</i> , 2017, 66, 1114-1117.	1.8	26
75	Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. <i>Estudio de 686 casos en 73 centros. Medicina Clínica</i> , 2017, 149, 61-71.	0.3	17
76	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , 2017, 37, 109-118.	1.8	73
77	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 61-71.	0.1	4
78	Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4000-4000.	0.8	31
79	The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments. <i>Oncotarget</i> , 2017, 8, 106151-106152.	0.8	5
80	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2448.	1.4	10
81	Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 117-131.	0.1	0
82	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016, 65, 719-726.	1.8	883
83	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1923-1936.	0.9	15
84	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 511.e1-511.e22.	0.1	2
85	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , 2016, 65, 864-865.	1.8	6
86	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016, 34, 597-602.	0.8	72
87	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , 2016, 64, 1090-1098.	1.8	567
88	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 835-853.	0.6	1,365
89	Pattern of tumor progression in liver cancer: The missing partner in trial design. <i>Hepatology</i> , 2015, 62, 674-676.	3.6	10
90	Reply. <i>Hepatology</i> , 2015, 62, 978-979.	3.6	0

#	ARTICLE	IF	CITATIONS
91	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, e105.	2.1	8
92	Does ramucirumab deserve a second chance for liver cancer?. <i>Lancet Oncology</i> , The, 2015, 16, 751-752.	5.1	3
93	Systemic Treatment: Expecting Further Success. <i>Digestive Diseases</i> , 2015, 33, 590-597.	0.8	1
94	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015, 275, 698-707.	3.6	115
95	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2cm. <i>Journal of Hepatology</i> , 2015, 62, 150-155.	1.8	46
96	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. <i>Hepatology</i> , 2015, 61, 526-536.	3.6	286
97	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. <i>Seminars in Liver Disease</i> , 2014, 34, 444-455.	1.8	112
98	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 554-563.	0.8	33
99	Systemic treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 921-935.	1.0	9
100	FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: Could a negative result be accepted as positive?. <i>Journal of Hepatology</i> , 2014, 61, 164-165.	1.8	3
101	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014, 61, 318-324.	1.8	203
102	Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. <i>Hepatology</i> , 2013, 58, 2023-2031.	3.6	217
103	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013, 49, 3412-3419.	1.3	218
104	Treatment of Hepatocellular Carcinoma with Radioembolization: Gathering Assumptions for Trial Design. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1197-1199.	0.2	2
105	If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?. <i>Liver International</i> , 2013, 33, 1454-1456.	1.9	5
106	Evoluci3n natural y estratificaci3n del carcinoma hepatocelular. <i>Clinical Liver Disease</i> , 2013, 2, S333-S363.	1.0	0
107	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and) Tj ETQq1 1 0.784314 rgBT /Overlock 61, 1481-1487.	6.1	154
108	Management of HCC. <i>Journal of Hepatology</i> , 2012, 56, S75-S87.	1.8	509

#	ARTICLE	IF	CITATIONS
109	Natural history and staging for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 183-185.	1.0	6
110	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012, 56, 103-108.	1.8	142
111	Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , 2012, 56, 1317-1323.	1.8	159
112	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012, 56, 1330-1335.	1.8	436
113	The Search for an Effective Partner for Sorafenib: The Failure of Doxorubicin. <i>Gastroenterology</i> , 2011, 140, 1687-1688.	0.6	1
114	Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques. <i>Hepatology</i> , 2011, 54, 2238-2244.	3.6	101
115	Medical treatments: in association or alone, their roles and their future perspectives. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 420-421.	1.4	1
116	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010, 51, 2020-2029.	3.6	268
117	Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects. <i>Seminars in Liver Disease</i> , 2010, 30, 061-074.	1.8	945
118	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , 2010, 42, S242-S248.	0.4	31
119	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. <i>Annual Review of Medicine</i> , 2010, 61, 317-328.	5.0	229
120	Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2009, 50, 791-798.	3.6	253
121	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 616-623.	2.0	403
122	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2009, 29, 148-158.	1.9	22
123	α -Fetoprotein for Hepatocellular Carcinoma Diagnosis: The Demise of a Brilliant Star. <i>Gastroenterology</i> , 2009, 137, 26-29.	0.6	89
124	Sorafenib for Hepatocellular Carcinoma: Global Validation. <i>Gastroenterology</i> , 2009, 137, 1171-1173.	0.6	5